Health Care Reform's Pricing Impact: 340B Purchasers See Initial 10% Decline in Brand Prices
This article was originally published in RPM Report
Executive Summary
How big an impact do the new Medicaid rebate rules have on prices? There's now way to tell for sure, but prices files analyzed for the 340B program offer a pretty good clue.
You may also be interested in...
Pharma's Stake In Essential Health Benefits
The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
340B: A Test Market for Health Care Reform?
The 340B program got a lot of attention from pharmaceutical industry lobbyists during the health care reform debate. Now it may be getting more attention from the commercial side of the business. Expanded discounts remains a legislative threat—but increased sales to “safety net” purchasers is also a business opportunity.
340B: A Test Market for Health Care Reform?
The 340B program got a lot of attention from pharmaceutical industry lobbyists during the health care reform debate. Now it may be getting more attention from the commercial side of the business. Expanded discounts remains a legislative threat—but increased sales to “safety net” purchasers is also a business opportunity.